Valor202020212022202320242025TTMGastos comerciales, generales y administrativos1.73 B2 B2.01 B2.15 B2.32 B2.38 B2.38 BInvestigación y desarrollo463 M508 M539 M614 M686 M698 M698 MBeneficio operativo2.15 B2.68 B2.83 B2.94 B5.91 B6.17 B3.35 BTotal de ingresos no operativos-17 M-48 M-40 M159 M19 M36 M36 MGastos por intereses, netos de intereses capitalizados231 M224 M221 M239 M225 M222 M222 MIngresos no operativos, una vez deducidos los gastos por intereses-243 M-268 M-275 M-79 M-202 M-180 M-180 MIngresos/gastos extraordinarios-5 M-4 M14 M-1 M-4 M-6 M-6 MBeneficio antes de impuestos2 B2.49 B2.66 B2.94 B3.13 B3.36 B3.36 BParticipación en los beneficios———————Impuestos360 M454 M545 M596 M637 M687 M687 MParticipación minoritaria-2 M-3 M-3 M-4 M10 M00Otros ingresos/gastos después de impuestos-11 M2 M-13 M8 M6 M8 M8 MBeneficio neto antes de actividades interrumpidas1.64 B2.04 B2.11 B2.34 B2.49 B2.67 B2.67 BOperaciones suspendidas———————Beneficio neto1.64 B2.04 B2.11 B2.34 B2.49 B2.67 B2.67 BAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas1.64 B2.04 B2.11 B2.34 B2.49 B2.67 B2.67 BBeneficio básico por acción3.444.294.515.085.476.036.03Beneficio por acción diluido3.424.274.495.075.476.026.02Número medio de acciones ordinarias475.5 M474.35 M468.89 M461.17 M454.2 M443.44 M1.78 BAcciones diluidas478.57 M476.72 M470.38 M462.27 M454.85 M443.83 M1.78 BEBITDA2.59 B3.13 B3.29 B3.43 B6.4 B6.66 B3.84 BEBIT2.15 B2.68 B2.83 B2.94 B5.91 B6.17 B3.35 BCosto de los ingresos2.06 B2.3 B2.45 B2.56 B2.72 B2.67 B2.67 BOtros costes de producción105 M46 M76 M115 M97 M68 M68 MAmortización y depreciación (flujo de caja)441 M448 M465 M491 M497 M487 M487 M
Zoetis Inc Class A
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total revenue. Contemporaneous with the spinoff in June 2013 S&P Dow Jones Indices announced that Zoetis would replace First Horizon National Corporation in the S&P 500 stock market index.